U.S. patent application number 15/641451 was filed with the patent office on 2017-10-19 for transdermal therapeutic systems containing 4-n-butyl-resorcinol.
This patent application is currently assigned to BEIERSDORF AG. The applicant listed for this patent is Ludger KOLBE, Cathrin SCHERNER, Karl-Heinz WOELLER, Rainer WOLBER. Invention is credited to Ludger KOLBE, Cathrin SCHERNER, Karl-Heinz WOELLER, Rainer WOLBER.
Application Number | 20170296692 15/641451 |
Document ID | / |
Family ID | 43734633 |
Filed Date | 2017-10-19 |
United States Patent
Application |
20170296692 |
Kind Code |
A1 |
WOELLER; Karl-Heinz ; et
al. |
October 19, 2017 |
TRANSDERMAL THERAPEUTIC SYSTEMS CONTAINING 4-N-BUTYL-RESORCINOL
Abstract
A method for the treatment of a local pigmentation disorder
comprises applying to skin affected by the disorder a transdermal
therapeutic system which comprises 4-n-butylresorcinol as an active
ingredient.
Inventors: |
WOELLER; Karl-Heinz;
(Hamburg, DE) ; KOLBE; Ludger; (Dohren, DE)
; SCHERNER; Cathrin; (Norderstedt, DE) ; WOLBER;
Rainer; (Hamburg, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
WOELLER; Karl-Heinz
KOLBE; Ludger
SCHERNER; Cathrin
WOLBER; Rainer |
Hamburg
Dohren
Norderstedt
Hamburg |
|
DE
DE
DE
DE |
|
|
Assignee: |
BEIERSDORF AG
Hamburg
DE
|
Family ID: |
43734633 |
Appl. No.: |
15/641451 |
Filed: |
July 5, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13499861 |
Jun 25, 2012 |
|
|
|
PCT/EP2010/004272 |
Jul 14, 2010 |
|
|
|
15641451 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 9/7061 20130101;
A61L 2300/216 20130101; A61K 9/7076 20130101; A61P 17/00 20180101;
A61L 2300/404 20130101; A61L 15/44 20130101; A61K 9/7053
20130101 |
International
Class: |
A61L 15/44 20060101
A61L015/44; A61K 9/70 20060101 A61K009/70; A61K 9/70 20060101
A61K009/70; A61K 9/70 20060101 A61K009/70 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 9, 2009 |
DE |
102009048973.8 |
Claims
1. A method for the treatment of a local pigmentation disorder,
wherein the method comprises applying to skin affected by the
disorder a transdermal therapeutic system which comprises
4-n-butylresorcinol as an active ingredient.
2. The method of claim 1, wherein the local pigmentation disorder
comprises local hyperpigmentation.
3. The method of claim 1, wherein the local pigmentation disorder
comprises age spots.
4. The method of claim 1, wherein the local pigmentation disorder
comprises freckles.
5. The method of claim 1, wherein the local pigmentation disorder
comprises post-inflammatory hyperpigmentation.
6. The method of claim 1, wherein the local pigmentation disorder
comprises melasma.
7. The method of claim 1, wherein the transdermal therapeutic
system is employed in the form of a self-adhesive flat bandage.
8. The method of claim 1, wherein the transdermal therapeutic
system is employed in the form of at least one of a cosmetic
plaster and a medicinal plaster.
9. The method of claim 1, wherein the transdermal therapeutic
system is employed in the form of a matrix system.
10. The method of claim 9, wherein the matrix is selected from
nonpolar matrices based on synthetic and natural rubber, polar wet
adhesive films based on polyacrylic acid/polyvinyl alcohol,
nonpolar matrices based on polyacrylic acid copolymers, polar
anhydrous gel matrices based on polyacrylic
acid/polyvinylpyrrolidone, nonpolar polyisobutylene matrices, and
polar water gel matrices based on agar agar/polyacrylic acid.
11. The method of claim 9, wherein the matrix is selected from
polyisobutylene matrices.
12. The method of claim 9, wherein the matrix is selected from
water gel matrices based on agar agar/polyacrylic acid.
13. The method of claim 1, wherein the transdermal therapeutic
system comprises from 0.001% to 10% by weight of
4-n-butylresorcinol, based on a total weight of the system.
14. The method of claim 1, wherein the transdermal therapeutic
system comprises from 0.01% to 1% by weight of
4-n-butylresorcinol.
15. The method of claim 11, wherein the matrix has a layer
thickness of from 0.15 mm to 1.00 mm.
16. The method of claim 12, wherein the matrix has a layer
thickness of from 0.15 mm to 1.00 mm.
17. The method of claim 11, wherein the matrix has a layer
thickness of from 0.20 mm to 0.50 mm.
18. The method of claim 12, wherein the matrix has a layer
thickness of from 0.20 mm to 0.50 mm.
19. The method of claim 1, wherein the transdermal therapeutic
system comprises from 0.001% to 10% by weight of one or more
penetration accelerators.
20. The method of claim 19, wherein the one or more penetration
accelerators comprise at least one of isopropyl palmitate and
isopropyl myristate.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a divisional of U.S. application
Ser. No. 13/499,861, the entire disclosure of which is expressly
incorporated by reference herein, which is a National Stage entry
of PCT/EP2010/04272, filed Jul. 14, 2010, which claims priority
under 35 U.S.C. 119 of German Patent Application 10 2009 048 073.8,
filed Oct. 9, 2009.
BACKGROUND OF THE INVENTION
1. Field of the Invention
[0002] The present invention relates to transdermal therapeutic
systems, self-adhesive flat bandages, in particular cosmetic and
medicinal plasters, containing 4-n-butylresorcinol.
2. Discussion of Background Information
[0003] Melanocytes are responsible for the pigmenting of the skin;
these are found in the lowest layer of the epidermis, the Stratum
basale, alongside the basal cells as pigment-forming cells which,
depending on the skin type, occur either individually or in
clusters of varying size.
[0004] Melanocytes contain, as characteristic cell organelles,
melanosomes, in which the melanin is formed. Inter alia, upon
stimulation by UV radiation, melanin is formed to a greater extent.
It is transported via the living layers of the epidermis
(keratinocytes) ultimately into the horny layer (comeocytes) and
brings about a more or less pronounced brownish to brown-black skin
color.
[0005] Melanin is formed as the end stage of an oxidative process
in which tyrosine is converted, under the co-action of the enzyme
tyrosinase, via several intermediates, to the brown to brown-black
eumelanins (DHICA and DHI melanin), or, with the participation of
sulfur-containing compounds, to the reddish pheomelanin. DHICA and
DHI melanin are formed via the common intermediates dopaquinone and
dopachrome. The latter, sometimes with the participation of further
enzymes, is converted either to indole-5,6-quinonecarboxylic acid
or into indole-5,6-quinone, from which the two specified eumelanins
are formed.
[0006] The formation of pheomelanin proceeds inter alia via the
intermediates dopaquinone and cysteinyldopa. The expression of the
melanin-synthesizing enzymes is controlled by a specific
transcription factor (microphthalmia-associated transcription
factor, MITF). Besides the described enzymatic processes of the
melanin synthesis, further proteins are also of importance for the
melanogenesis in the melanosomes. An important role here appears to
be attributed to the so-called p-protein, although the exact
function is still unclear.
[0007] As well as the above-described process of the melanin
synthesis in the melanocytes, the transfer of the melanosomes,
their stay in the epidermis and also their degradation and the
degradation of the melanin are also of decisive importance for the
pigmenting of the skin. It was shown that the PAR-2 receptor is
important for the transport of the melanosomes from the melanocytes
into the keratinocytes (M. Seiberg et al., 2000, J. Cell. Sci.,
113:3093-101).
[0008] In addition, the size and shape of the melanosomes have an
influence on their light-scattering properties and thus the color
appearance of the skin. For example, in black Africans there are
more large spheroidal individual melanosomes whereas in Caucasians,
smaller melanosomes occurring in groups are to be found.
[0009] Problems with hyperpigmentation of the skin have a wide
variety of causes and/or are accompanying phenomena of many
biological processes, e.g. UV radiation (e.g. freckles, Ephelides),
genetic disposition, incorrect pigmentation of the skin during
wound healing or scarring (post-inflammatory hyperpigmentation) or
skin aging (e.g. Lentigines seniles).
[0010] After inflammatory reactions, the pigmentation system of the
skin reacts with sometimes opposite reactions. This can lead either
to post-inflammatory hyperpigmentations or hypopigmentations.
Post-inflammatory hypomelanoses often arise inter alia in
conjunction with atopy, Lupus erythematosus and psoriasis. The
different reaction forms of the pigmentation system of human skin
as a result of inflammatory phenomena are understood only very
incompletely.
[0011] Problems with post-inflammatory hyperpigmentation often
occur in darker skin types. Particularly in colored males, the
problem of Pseudofollikulitis barbae is known, which is associated
with cosmetically undesired incorrect pigmentation and/or leads to
this. Forms of melasma, which occur in particular in women of
Asiatic origin on the face and on the decolletage area, and also
various forms of irregular pigmentation of the skin are also types
of post-inflammatory hyperpigmentations. In addition, dark circles
around the eyes are also considered to be a form of
post-inflammatory hyperpigmentations, the underlying inflammation
in most cases proceeding without clinical manifestations.
[0012] In many cases, post-inflammatory incorrect pigmentation of
this type is increased further by the action of sunlight (UV light)
without resulting in a UV-induced inflammation (sunburn).
[0013] Active ingredients and preparations are known which
counteract skin pigmentation. In practical use are essentially
preparations based on hydroquinone, although, on the one hand,
these only exhibit their effect after application for several
weeks, and, on the other hand, their excessively long application
is unacceptable for toxicological reasons. Albert Kligman et al.
has developed a so-called triformula which constitutes a
combination of 0.1% tretinoin, 5.0% hydroquinone, 0.1%
dexamethasone (A. Kligman, 1975, Arch. Dermatol., 111:40-48).
However, this formulation too is highly disputed on account of
possible irreversible changes in the pigmentation system of the
skin.
[0014] In addition, skin-peeling methods (chemical and mechanical
peels) are used, although these often lead to inflammatory
reactions and, on account of post-inflammatory hyperpigmentations
which may subsequently arise, can even lead to greater pigmentation
instead of reduced pigmentation. All of these customary methods,
which are also used for treating post-inflammatory
hyperpigmentations, are characterized by distinct side effects.
[0015] Cosmetic preparations with 4-n-butylresorcinol are known,
for example from EP 1 490 017.
[0016] 4-n-Butylresorcinol, CAS[18979-61-8], is characterized by
the chemical structure
##STR00001##
[0017] 4-n-Butylresorcinol is also called rucinol or lucinol. It
inhibits the production of melanin by inhibiting the enzyme
tyrosinase required for the synthesis of melanin (melanogenesis).
The production of melanin is firstly inhibited, then the production
of black melanin, which is responsible for the intense coloration
of pigment spots, is blocked.
[0018] 4-n-Butylresorcinol has the formulatory disadvantage that it
has a tendency to discolor--and to discolor cosmetic or
dermatological preparations comprising it.
[0019] Transdermal therapeutic systems ("TTS") are known per se. A
disadvantage of TTS is that usually only ca. 10% to 20% of the
active ingredient content of the plaster are released during the
application time. (Kommentar zum Europaischen Arzneibuch
[Commentary on the European pharmacopeia], Wissenschaftliche
Verlagsgesellschaft Stuttgart, status: update 2009).
SUMMARY OF THE INVENTION
[0020] The present invention provides a transdermal therapeutic
system, which system comprises 4-n-butylresorcinol as an active
ingredient.
[0021] In one aspect, the system may be present as a self-adhesive
flat bandage, e.g., as a cosmetic plaster and/or a medicinal
plaster.
[0022] In another aspect, the system may be present in the form of
a matrix system. For example, the matrix may be selected from
nonpolar matrices based on synthetic and natural rubber, polar wet
adhesive films based on polyacrylic acid/polyvinyl alcohol,
nonpolar matrices based on polyacrylic acid copolymers, polar
anhydrous gel matrices based on polyacrylic
acid/polyvinylpyrrolidone, nonpolar polyisobutylene matrices, and
polar water gel matrices based on agar agar/polyacrylic acid.
[0023] In yet another aspect, the system of the present invention
may comprise from 0.001% to 10%, e.g., from 0.01% to 1% by weight
of 4-n-butylresorcinol, based on the total weight of the
system.
[0024] In a still further aspect, the system may comprise one or
more penetration accelerators such as, e.g., isopropyl palmitate
and/or isopropyl myristate. For example, the one or more
penetration accelerators may be present at a concentration of from
0.001% to 10%, e.g., from 0.01% to 7.5% or from 0.1% to 5% by
weight.
[0025] In another aspect, the system may release
4-n-butylresorcinol at a rate of >30%/24 h, e.g., at a rate of
55-65%/24 h.
[0026] The present invention also provides a transdermal
therapeutic system that comprises from 0.01% to 1% by weight of
4-n-butylresorcinol and from 0.1% to 5% by weight of one or more
penetration accelerators which comprise isopropyl palmitate and/or
isopropyl myristate.
[0027] In one aspect, the system may be present in the form of a
matrix system, and the matrix may be selected from polar water gel
matrices based on agar agar/polyacrylic acid and nonpolar
polyisobutylene matrices.
[0028] In another aspect, the system may release
4-n-butylresorcinol at a rate of >30%/24 h.
[0029] The present invention also provides a method for the
treatment of a local pigmentation disorder. The method comprises
the application of the transdermal therapeutic system of the
present invention set forth above (including the various aspects
thereof) onto skin affected by the disorder.
[0030] In one aspect of the method, the disorder may comprise local
hyperpigmentation such as, e.g., one or more of age spots,
freckles, post-inflammatory hyperpigmentation (e.g. as a result of
Pseudofollikulitis barbae), and melasma.
DETAILED DESCRIPTION OF THE INVENTION
[0031] To produce an effective self-adhesive plaster comprising
4-butylresorcinol with optimized release for the treatment of
pigment disorders of the skin, various self-adhesive matrix systems
with 1% of the active ingredient were produced and investigated
with regard to their release properties after 24 hours on pig skin
by means of Franz cells:
[0032] A nonpolar matrix based on synthetic and natural rubber
(KA)
[0033] A polar wet adhesive film based on polyacrylic
acid/polyvinyl alcohol (FKF)
[0034] A nonpolar matrix based on a polyacrylic acid copolymer
(PAC)
[0035] A polar anhydrous gel matrix based on polyacrylic
acid/polyvinylpyrrolidone (WFG)
[0036] A nonpolar polyisobutylene matrix (PIB)
[0037] A polar water gel matrix based on agar agar/polyacrylic acid
(WG)
[0038] Results of the active ingredient release of different matrix
systems:
TABLE-US-00001 (KA) (FKF) (PAC) (WFG) (PIB) (WG) 7.4% 17.8% 18.1%
20.6% 22.2% 34.0%
[0039] Based on the above first results, the nonpolar
polyisobutylene matrix and the polar water gel matrix were selected
for further optimization experiments with regard to the release of
4-n-butylresorcinol.
[0040] The active ingredient release can advantageously be
controlled by virtue of the layer thickness of the TTS.
[0041] For both systems, PIB and WG, in each case samples with a
layer thickness of 1.00; 0.75; 0.50; 0.30 and 0.15 mm were produced
and investigated.
[0042] Results of the active ingredient release of different matrix
layer thicknesses:
TABLE-US-00002 1.00 mm 0.75 mm 0.50 mm 0.30 mm 0.15 mm (PIB) 22.2%
27.4% 26.7% 42.7% 46.4% (WG) 34.0% 48.3% 41.8% 66.2% 56.8%
[0043] As a compromise between percentage active ingredient
release, absolute released amount of active ingredient and
handlability of the finished self-adhesive plaster, for both matrix
systems, a layer thickness between 1.00 mm and 0.01 mm, preferably
0.50 and 0.20 mm and very particularly preferably of 0.30 mm is
considered. In particular, the self-adhesive patch based on a polar
water gel according to the invention exhibits, with around 65% of
the active ingredient, a surprisingly high release compared to
customary plaster applications.
[0044] In order to likewise bring the PIB matrix system into this
active ingredient release range, further experiments were carried
out by means of incorporating customary additives for increasing
the hydrophilicity of the matrix, and also customary penetration
accelerators.
[0045] The incorporation of 35% cellulose into the PIB matrix
revealed no significant difference in the active ingredient release
compared with a matrix not filled with cellulose.
[0046] As customary penetration accelerators, in each case 5%
isopropyl palmitate (IPP) and 5% isopropyl myristate (IPM) were
then incorporated into a corresponding PIB matrix, and the release
of 4-n-butylresorcinol from the end products produced therefrom of
layer thickness 0.30 mm was determined.
[0047] Results of the PIB matrix active ingredient release of
different penetration accelerators:
TABLE-US-00003 PIB matrix PIB matrix plus 5% IPP plus 5% IPM
Release of 4-n-butyl-resorcinol 33.2% 61.3%
[0048] Surprisingly, the addition of 5% IPM exhibited almost twice
as high an active ingredient release from the PIB matrix as the
addition of the homologous penetration accelerator IPP.
[0049] With around 61% release of 4-n-butylresorcinol from the
nonpolar PIB matrix, it was possible to achieve an analogous order
of magnitude as from the polar water gel matrix with around
65%.
[0050] Examples of the preparation of polar self-adhesive water gel
matrices are described in DE 102 60 872.
[0051] Examples of the preparation of nonpolar self-adhesive PIB
matrices are described in EP 1335755.
[0052] Suitable carrier materials for polar and nonpolar
self-adhesive patches according to the invention with optimized
active ingredient release for the treatment of pigment disorders of
the skin are all customary flat layered materials such as, for
example, woven fabrics, films, nonwoven fabrics etc. In the case of
the last-mentioned carrier materials, in particular so-called
non-wovens of small layer thickness are advantageous because these
are barely noticeable in visual terms on the matrices against the
skin. The use of very thin, layer thickness below 100 .mu.m,
flexible and transparent to translucent polymer films, in
particular those polyurethane films produced from aqueous
dispersion, is particularly advantageous.
[0053] However, it is also possible to use films from all other
known polymer films, such as e.g. polyethylene, ethylvinylacetate
etc. In the case of the polyisobutylene matrix, when using carrier
materials with significantly different water vapor transmission
rates (WVTR) of 5933.5 g/m.sup.2*24 h (viscose) via 1509.9
g/m.sup.2*24 h (polyurethane) to 25.7 g/m.sup.2*24 h
(polyethylene), no significant differences could be established in
the active ingredient release. The reason for this is the
hydrophobicity of the PIB matrix as determining factor for the
WVTR. When using hydrophilic fillers, such as e.g. cellulose or
polyacrylic acid derivatives, in a PIB matrix, however, carrier
materials of different WVTR can become relevant again as the
determining factor of the active ingredient release.
[0054] In the case of the water gel, the active ingredient release
can be significantly influenced by the WVTR of the carrier material
used. Thus, e.g. samples with viscose carrier exhibited a 14%
higher active ingredient release compared with samples with PU
carriers.
[0055] Since the water gel matrices and also polyisobutylene
matrices according to the invention are transparent to at most
translucent, patches laminated with the above-described films as
carrier materials are barely noticeable in visual terms and can
therefore also be used inconspicuously over prolonged periods. As a
result of appropriate coloring of the matrices or covering with a
precolored carrier, a patch according to the invention, however,
can also be produced in an inconspicuous skin shade.
[0056] Self-adhesive patches according to the invention can have
any desired shape and size, e.g. round, rectangular, square etc. It
is particularly advantageous that patches according to the
invention based on PIB and on WG can be rightly cut by the user
into any desired shape and size using standard commercial scissors
in order to tailor the patch exactly to the desired treatment
area.
[0057] It has been found that the water gel matrices and
polyisobutylene matrices according to the invention have proven to
be particularly easy to handle and effective particularly for the
treatment of local hyperpigmentations such as age spots, freckles,
post-inflammatory hyperpigmentations (e.g. as a consequence of
Pseudofollikulitis barbae) if they are present in round to oval
form with a diameter of .ltoreq.20 mm, preferably .ltoreq.15 mm,
very particularly preferably .ltoreq.10 mm.
[0058] It has been found that the water gel matrices and also
polyisobutylene matrices according to the invention have proven to
be particularly easy to handle and effective particularly for the
treatment of local hyperpigmentations such as melasma if they have
an area .gtoreq.25 cm.sup.2, preferably .gtoreq.15 cm.sup.2, very
particularly preferably .gtoreq.4 cm.sup.2.
EXAMPLES
Example 1: Wet Adhesive Film Based on Polyacrylic Acid/Polyvinyl
Alcohol (FKF)
TABLE-US-00004 [0059] % by weight Polyvinyl alcohol 68.0
Polyacrylic acid 16.5 Polyethylene glycol 400 9.5 Glycerol 5.0
4-n-Butylresorcinol 1.0
Example 2: Polar Anhydrous Gel Matrix, Polyacrylic
Acid/Polyvinylpyrrolidone Base (WFG)
TABLE-US-00005 [0060] % by weight Dexpanthenol 3.0 Propanediol 5.0
Polyethylene glycol 400 18.0 Polyacrylic acid 22.5
Polyvinylpyrrolidone 3.5 Silicon dioxide 4.0 Glycerol 43.0
4-n-Butylresorcinol 1.0
Example 3: Nonpolar Polyisobutylene Matrix (PIB)
TABLE-US-00006 [0061] % by weight PIB 12 21.5 PIB 80 20.0 PIB 12
10.0 Cellulose 33.0 Isopropyl myristate 5.0 Decyl oleate 9.5
4-n-Butylresorcinol 1.0
Example 4: Polar Water Gel Matrix Based on Agar Agar/Polyacrylic
Acid (WG)
TABLE-US-00007 [0062] % by weight Water 49.1 Sorbitol 15.7 Agar
agar 2.0 Glycerol 20.0 Polyacrylic acid 8.0 NaOH 45% 4.2
4-n-Butylresorcinol 1.0
* * * * *